| Issue Date | Title | Author(s) |
| 1 | 2023 | Case Report-Right Atrial Mass: a Very Rare Presentation of Endometrial Cancer Metastasis | Ertürk, Emre ; Söyler, Onur; Pehlivan, Fatma Seher; Arslan, Çagatay |
| 2 | 2023 | Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: a Multicenter Study From the Turkish Oncology Group Kidney Cancer Consortium | Erol, Cihan; Yekeduz, Emre; Tural, Deniz; Karakaya, Serdar; Şentürk Öztaş, Nihan; Uçcar, Gökhan; Kılıçkap, Saadettin; Arslan, Çağatay |
| 3 | 2025 | Comparison of Two Alternative Sequences With Cabazitaxel and 177lu-P in Metastatic Castration-Resistant Prostate Cancer: a Retrospective Multicenter Study (Lucas) | Bolek, Hatice; Yazgan, Sati Coskun; Ceylan, Furkan; Esteban-Villarrubia, Jorge; Arslan, Cagatay ; Kus, Tulay; Urun, Yuksel |
| 4 | 2022 | Cutaneous Metastasis of Bladder Urothelial Carcinoma; a Rare Conditions | Oztuerk, Hakan; Yurtsever, Selin; Ozer, Arzum; Arslan, Cagatay ; Tekeli, Aysun; Pehlivan, Fatma Seher |
| 5 | 2023 | The Efficacy of Immunotherapy and Chemoimmunotherapy in Patients With Advanced Rare Tumors: a Turkish Oncology Group (tog) Study | Güven, Deniz Can; Aykan, Musa Barış; Muglu, Harun; Bayram, Ertuğrul; Helvacı, Kaan; Dursun, Bengue; Celayir, Melisa; Arslan, Çağatay |
| 6 | 2025 | Enhancing Outcomes in mCRPC: The Impact of Androgen Receptor Inhibitor Sequencing Before 177Lu-PSMA Therapy | Yazgan, Sati Coskun; Kayas, Kamil; Arslan, Cagatay ; Kapar, Caner; Oztekin, Sura; Ceylan, Furkan; Urun, Yuksel |
| 7 | 2023 | External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (imdc): Results From the Turkish Oncology Group Kidney Cancer Consortium (tkcc) Database | Yekeduz, Emre; Karakaya, Serdar; Erturk, Ismail; Tural, Deniz; Ucar, Gokhan; Oztas, Nihan Senturk; Arikan, Rukiye; Arslan, Çağatay |
| 8 | 2023 | Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice | Tural D.; Arslan C. ; Selcukbiricik F.; Olmez O.F.; Akar E.; Erman M.; Ürün Y. |
| 9 | 2024 | Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer | Tural, Deniz; Arslan, Cagatay ; Selcukbiricik, Fatih; Olmez, Omer Fatih; Akar, Emre; Erman, Mustafa; Ueruen, Yueksel |
| 10 | 2022 | Modified Docetaxel, Cisplatin, and 5-Fluorouracil Combination Regimen and Capecitabine Maintenance in Metastatic Gastric Cancer: Toxicity and Efficacy Results | Arslan, Cagatay ; Atilla, Fatos Dilan |
| 11 | 2021 | Nivolumab in Metastatic Renal Cell Carcinoma: Results From the Turkish Oncology Group Kidney Cancer Consortium Database | Yekeduz, Emre; Erturk, Ismail; Tural, Deniz; Karadurmus, Nuri; Karakaya, Serdar; Hizal, Mutlu; Arikan, Rukiye; Arslan, Cagatay |
| 12 | 2024 | Objective Response Rate Is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors | Tural, Deniz; Arslan, Çagatay ; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Erman, Mustafa; Ürün, Yüksel; Erdem, Dilek |
| 13 | 2023 | Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (propel): Final Prespecified Overall Survival Results of a Randomised, Double-Blind, Phase 3 Trial | Saad, F.; Clarke, N.W.; Oya, M.; Shore, N.; Procopio, G.; Guedes, J.D.; Arslan, Çağatay |
| 14 | 2024 | Perceptions and Expectations: a Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer | Bölek, Hatice; Arslan, Çagatay ; Başaran, Mert; Cicin, Irfan; Ozguroglu, Mustafa; Tural, Deniz; Ürün, Yüksel |
| 15 | 2023 | Perspectives and Knowledge About Fertility Preservation Strategies Among Female Cancer Patients in Turkey | Emirdar, Volkan ; Karatasli, Volkan; Acet, Ferruh; Okay, Gulin ; Gode, Funda ; Karabulut, Alaattin; Arslan, Cagatay |
| 16 | 2024 | Phase 2 Study of the Antitumour Activity and Safety of Simlukafusp Alfa (fap-Il2v) Combined With Atezolizumab in Patients With Recurrent And/Or Metastatic Cervical Squamous Cell Carcinoma | Verlingue, Loic; Italiano, Antoine; Prenen, Hans; Alia, Eva Maria Guerra; Tosi, Diego; Perets, Ruth; Lugowska, Iwona; Arslan, Cagatay |
| 17 | 2024 | Phase Ii Study To Determine the Antitumor Activity and Safety of Simlukafusp Alfa (fap-Il2v) Combined With Atezolizumab in Esophageal Cancer | Prenen, Hans; Deva, Sanjeev; Keam, Bhumsuk; Lindsay, Colin R.; Lugowska, Iwona; Yang, James C.; Longo, Federico; Arslan, Cagatay |
| 18 | 2022 | The Relationship Between Pan-Immune Value and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab in the Second Line and Beyond: a Turkish Oncology Group Kidney Cancer Consortium (tkcc) Study | Yekeduz, Emre; Tural, Deniz; Erturk, Ismail; Karakaya, Serdar; Erol, Cihan; Ercelep, Ozlem; Arslan, Cagatay |
| 19 | 2022 | The Relationship Between Systemic Immune Inflammation Index and Survival in Patients With Metastatic Renal Cell Carcinomatreated Withtyrosine Kinase Inhibitors | Yucel, Kadriye Bir; Yekeduz, Emre; Karakaya, Serdar; Tural, Deniz; Erturk, Ismail; Erol, Cihan; Ercelep, Ozlem; Arslan, Cagatay |
| 20 | 2023 | The Safety and Efficacy of First-Line Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma: a Multicenter Real-World Study From Turkey | Akyildiz, A.; Guven, D.C.; Ozluk, A.A.; Ismayilov, R.; Mutlu, E.; Unal, O.U.; Yildiz, I.; Arslan, Cagatay MD |
Loading...
5
0
20
0
false